Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 30, 2019

View Archived Issues

Neutrophils stick with dipeptidase in lung, liver

OncoNano receives grant to support development of oncology product candidate ONM-500

Novel Chemerin GPCR agonist OK-113 exhibits anti-inflammatory activity in DED mouse model

Discovery of a targeted covalent CDK14 inhibitor with a TAIRE kinase-biased selectivity profile

Pulmonary mucormycosis mouse model developed to test treatments

FDA accepts IND for clinical study of MR-301 for severe traumatic brain injury

First patient enrolled in phase IIa study of sepranolone

Immatics and Celgene collaborate to develop novel adoptive cell therapies

La Jolla Pharmaceutical receives European approval for Giapreza

Mirati Therapeutics compounds target the PRC2 EED binding site

Denali Therapeutics synthesizes brain-penetrant LRRK2 kinase inhibitors for the treatment of PD

New antifilarials CBR-417 and CBR-490 validated in models in vivo

Shanghai Dongxi Zhihui Biological Medicine patents beta-amyloid production inhibitors

Preclinical and first clinical data for the novel Ox1R antagonist, JNJ-61393215

NeuracleGenetics describes new programmed cell death protein-1 variants

New DNA-CAR modified T cells presented by Arizona State University

Janssen discloses tau-binding molecules

Beijing Kawin Technology Share-Holding discloses anti-IL-4RA antibodies

Soft sell delivers CRISPR to TNBC

AbbVie discontinues development of Rova-T following phase III MERU findings

ASCLEPIOS I and II trials of ofatumumab in relapsing MS meet primary endpoint

Esperion reports phase II topline results for bempedoic acid/ezetimibe combination tablet

Orinove studies ORIN-1001 in advanced solid tumors and relapsed/refractory metastatic breast cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...